(OMI) Owens & Minor - Ratings and Ratios
Medical, Surgical, Home, Diabetes, Incontinence
OMI EPS (Earnings per Share)
OMI Revenue
Description: OMI Owens & Minor
Owens & Minor, Inc. is a global healthcare solutions company that operates through two primary segments: Products & Healthcare Services and Patient Direct. The company offers a diverse portfolio of medical and surgical supplies, including branded and proprietary products, as well as a range of services such as supplier management, analytics, and inventory management to healthcare providers. Additionally, Owens & Minor provides outsourced logistics and marketing solutions to suppliers and delivers products and services for in-home care, including diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment.
The companys Products & Healthcare Services segment is a significant player in the healthcare industry, serving multi-facility networks, independent hospitals, surgery centers, and physicians practices. The Patient Direct segment complements this by supplying a range of home medical equipment and patient care products, including ostomy, wound care, urology, and incontinence products. With a history dating back to 1882, Owens & Minor has established itself as a trusted partner in the healthcare ecosystem, leveraging its extensive network and expertise to drive growth and innovation.
From a technical analysis perspective, Owens & Minors stock (OMI) is currently trading at $8.33, with its SMA20 and SMA50 indicating a near-term uptrend. However, the SMA200 at $10.85 suggests a longer-term downtrend. The ATR of 0.43 (5.19%) indicates moderate volatility. Considering the
To validate this forecast, it is essential to closely monitor Owens & Minors future earnings reports, management guidance, and industry trends. Any significant changes in the companys financial performance, such as improvements in RoE, or shifts in the competitive landscape, could impact the stocks trajectory. By combining technical analysis with fundamental insights, investors can make more informed decisions about Owens & Minor, Inc. (OMI).
Additional Sources for OMI Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
OMI Stock Overview
Market Cap in USD | 680m |
Sector | Healthcare |
Industry | Medical Distribution |
GiC Sub-Industry | Health Care Distributors |
IPO / Inception | 1988-12-16 |
OMI Stock Ratings
Growth Rating | -31.3 |
Fundamental | -35.9 |
Dividend Rating | 7.46 |
Rel. Strength | -26.4 |
Analysts | 3.33 of 5 |
Fair Price Momentum | 7.99 USD |
Fair Price DCF | - |
OMI Dividends
Currently no dividends paidOMI Growth Ratios
Growth Correlation 3m | 28.9% |
Growth Correlation 12m | -83% |
Growth Correlation 5y | -67% |
CAGR 5y | 3.97% |
CAGR/Max DD 5y | 0.05 |
Sharpe Ratio 12m | -0.31 |
Alpha | -32.38 |
Beta | -0.162 |
Volatility | 68.33% |
Current Volume | 1272.4k |
Average Volume 20d | 1450.3k |
As of July 03, 2025, the stock is trading at USD 9.29 with a total of 1,272,358 shares traded.
Over the past week, the price has changed by +18.19%, over one month by +46.30%, over three months by +1.42% and over the past year by -29.83%.
Probably not. Based on ValueRay´s Fundamental Analyses, Owens & Minor (NYSE:OMI) is currently (July 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -35.89 and therefor a somewhat negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of OMI is around 7.99 USD . This means that OMI is currently overvalued and has a potential downside of -13.99%.
Owens & Minor has received a consensus analysts rating of 3.33. Therefor, it is recommend to hold OMI.
- Strong Buy: 2
- Buy: 0
- Hold: 2
- Sell: 2
- Strong Sell: 0
According to our own proprietary Forecast Model, OMI Owens & Minor will be worth about 8.6 in July 2026. The stock is currently trading at 9.29. This means that the stock has a potential downside of -7.1%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 9.5 | 2.3% |
Analysts Target Price | 10.4 | 12.3% |
ValueRay Target Price | 8.6 | -7.1% |